Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 5/20 | 0.54 |
| ▸ | GRM5 | P41594 | 9/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19797892 | 1.00 | GPR142 (0.54) | GPR142GRM5HSD11B1HSD11B2MAPT | |
| SCHEMBL17008877 | 1.00 | GPR142 (0.54) | GPR142GRM5HSD11B1HSD11B2MAPT | |
| SCHEMBL30168800 | 1.00 | GPR142 (0.54) | GPR142GRM5HSD11B1HSD11B2MAPT | |
| SCHEMBL23716713 | 0.87 | GPR142 (0.54) | GPR142GRM5HSD11B1HSD11B2MAPT | |
| SCHEMBL17020126 | 0.87 | GPR142 (0.54) | GPR142GRM5HSD11B1HSD11B2MAPT | |
| SCHEMBL19797904 | 0.85 | GPR142 (0.57) | GPR142GRM5HSD11B1HSD11B2 | |
| SCHEMBL19797905 | 0.85 | GPR142 (0.57) | GPR142GRM5HSD11B1HSD11B2 | |
| SCHEMBL19797895 | 0.85 | GPR142 (0.57) | GPR142GRM5HSD11B1HSD11B2 | |
| SCHEMBL30168795 | 0.85 | GPR142 (0.57) | GPR142GRM5HSD11B1HSD11B2 | |
| SCHEMBL30168796 | 0.85 | GPR142 (0.57) | GPR142GRM5HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715609-B | Cyclohexylbenzamide compounds | 伊莱利利公司 | 2023-01-10 | — | — | CN | disclosed |
| US-11214562-B2 | Cyclohexyl benzamide compounds | ELI LILLY AND COMPANY (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210292302-A1 | CYCLOHEXYL BENZAMIDE COMPOUNDS | ELI LILLY AND COMPANY | 2021-09-23 | — | — | US | disclosed |
| EP-3487840-B1 | CYCLOHEXYL BENZAMIDE COMPOUNDS | LILLY CO ELI (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2018014800-A1 | CYCLOHEXYL BENZAMIDE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2018-01-25 | — | — | WO | disclosed |
| WO-2018014337-A1 | 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide | ELI LILLY AND COMPANY (US) | 2018-01-25 | — | — | WO | disclosed |
| US-9861613-B2 | GPR142 agonist compounds | ELI LILLY AND COMPANY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170165234-A1 | GPR142 Agonist Compounds | ELI LILLY AND COMPANY | 2017-06-15 | — | — | US | disclosed |
| US-20170165234-A1 | GPR142 Agonist Compounds | ELI LILLY AND COMPANY | 2017-06-15 | — | — | US | disclosed |
| WO-2015120768-A1 | GPR142 AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292302-A1 | CYCLOHEXYL BENZAMIDE COMPOUNDS | CBR1, CNR1, IDH1 | GPR142 699/4885GRM5 3465/4885HSD11B1 1661/4885 |
| US-20170165234-A1 | GPR142 Agonist Compounds | GPR3, GPR142, GPR27 | GPR142 2/4885GRM5 376/4885HSD11B1 971/4885 |
| US-11214562-B2 | Cyclohexyl benzamide compounds | CBR1, CNR1, IDH1 | GPR142 699/4885GRM5 3465/4885HSD11B1 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.